BOLT Stock Price History and Quote Analysis: Insights for Investors
Bolt Biotherapeutics, Inc.
Stock Price Today
Bolt Biotherapeutics, Inc. (BOLT) stock declined over -0.37%, trading at $0.65 on NASDAQ, down from the previous close of $0.65. The stock opened at $0.66, fluctuating between $0.64 and $0.66 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Company Information
| Employees | 100 |
| Beta | 0.929 |
| Sales or Revenue | $7.88M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) stock price is $0.65 in the last trading session. During the trading session, BOLT stock reached the peak price of $0.66 while $0.64 was the lowest point it dropped to. The percentage change in BOLT stock occurred in the recent session was -0.37% while the dollar amount for the price change in BOLT stock was -$0.00.
The NASDAQ listed BOLT is part of Biotechnology industry that operates in the broader Healthcare sector. Bolt Biotherapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Bruce Hug M.D., Ph.D.
Senior Vice President of Clinical Devel. & Translational Medicine
Dr. Ming Yin Ph.D.
Vice President & Head of Biometrics
Dr. Nathan Ihle Ph.D.
Senior Vice President of Pharmaceutical Operations
Mr. Wesley Burwell
Vice President & Head of HR
Dr. Edgar G. Engleman M.D.
Founder & Independent Director
Mr. William P. Quinn
Chief Financial Officer & Sec.
Mr. Grant Yonehiro C.F.A., M.B.A.
Chief Bus. Officer
Dr. Edith A. Perez M.D.
Chief Medical Officer
Ms. Karen L. Bergman
Vice President of Investor Relations & Corporation Communications
Dr. Edgar George Engleman M.D.
Founder & Independent Director
Dr. Randall C. Schatzman Ph.D.
Chief Executive Officer & Director
BOLT's closing price is 1.03% higher than its 52-week low of $0.64 where as its distance from 52-week high of $1.56 is -58.49%.
Number of BOLT employees currently stands at 100.
Official Website of BOLT is: https://www.boltbio.com
BOLT could be contacted at phone 650 665 9295 and can also be accessed through its website. BOLT operates from 900 Chesapeake Drive, Redwood City, CA 94063, United States.
BOLT stock volume for the day was 67.57K shares. The average number of BOLT shares traded daily for last 3 months was 164.08K.
The market value of BOLT currently stands at $24.78M with its latest stock price at $0.65 and 38.26M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com